Recital 11, Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 31 Mar 2004cited 3×

For medicinal products for human use, the period for protection of data relating to pre-clinical tests and clinical trials should be the same as that provided for in Directive 2001/83/EC. For medicinal products for veterinary use, the period for protection of data relating to pre-clinical tests and clinical trials as well as safety and residue tests should be the same as that provided for in Directive 2001/82/EC.

  • Order of the Court (Eighth Chamber) of 14 May 2012. Sepracor Pharmaceuticals (Ireland) Ltd v European Commission.Decision

    14 May 2012 · 62011CO0477

  • Judgment of the General Court (Second Chamber) of 15 September 2015. Novartis Europharm Ltd v European Commission.Decision

    Thus, the sixth recital in the preamble to Regulation No 2309/93 stated expressly that ‘the same criteria [as those applicable to products authorised at national level] must be applied to medicinal products which are to be authorised by …

    15 Sep 2015 · 62012TJ0472

  • Judgment of the General Court (Fifth Chamber, Extended Composition) of 24 September 2025. Sanofi BV, anciennement Genzyme Europe BV v EuropeDecision

    According to recital 11 of Regulation No 726/2004, for medicinal products for human use, the period for protection of data relating to pre-clinical tests and clinical trials should be the same as that provided for in Directive 2001/83. …

    24 Sep 2025 · 62022TJ0483